Tyrosine-protein phosphatase non-receptor type 2 (PTPN2 (also known as TC-PTP))

Tyrosine-protein phosphatase non-receptor type 2 is an intracellular enzyme encoded by the *PTPN2* gene. It belongs to the protein tyrosine phosphatase family and functions primarily by dephosphorylating key receptor and non-receptor kinases involved in multiple cellular signaling cascades—including those mediated by insulin receptor (INSR), epidermal growth factor receptor (EGFR), colony-stimulating factor 1 receptor (CSF1R), platelet-derived growth factor receptor beta (PDGFRB), Janus kinases JAK1/JAK3/JAK2/Src family kinases/stat proteins STAT1/STAT3/STAT6. Through these actions it negatively regulates processes such as hematopoiesis, T-cell activation/differentiation via FYN/LCK dephosphorylation, macrophage differentiation via CSF1R dephosphorylation, cytokine-mediated responses through JAK/STAT pathway modulation—and thus plays critical roles in immunity/tolerance maintenance and metabolic balance. Dysregulation of this enzyme has been implicated in various pathologies including cancer development/progression/inflammation/cardiovascular diseases like atherosclerosis/metabolic disorders such as diabetes mellitus/type 1 diabetes/chronic inflammatory conditions like IBD/Crohn’s disease/rheumatoid arthritis. The enzyme exists in several isoforms determined by alternative splicing at the C-terminal region which affects substrate specificity/localization within cells.[1][2][3][5]

Other names

PTPN2TC-PTP (T-cell protein tyrosine phosphatase)Protein tyrosine phosphatase, non-receptor type 2

Drugs or compounds that target PTPN2 would generally act by inhibiting or modulating its phosphatase activity, thereby altering downstream phosphorylation-dependent signaling pathways such as JAK/STAT, EGFR, PDGFR, and insulin receptor signaling. This can impact immune cell activation, cytokine responses, cell growth/proliferation signals, and metabolic processes[1][2].